Scholarlink

<p>Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Site-directed multivalent conjugation of antibodies to ubiquitinated payloads

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月9日

查看全文
  • Angela F. el Hebieshy,
  • Zacharias Wijfjes,
  • Camille M. Le Gall,
  • Jim Middelburg,
  • Kim E. de Roode,
  • Felix L. Fennemann,
  • Marjolein Sluijter,
  • Thorbald van Hall,
  • Douwe J. Dijkstra,
  • Leendert A. Trouw,
  • Floris J. van Dalen,
  • Andrea Rodgers Furones,
  • Johan M. S. van der Schoot,
  • Ian Derksen,
  • Hans de Haard,
  • Bas van der Woning,
  • Cami M. P. Talavera Ormeño,
  • Bjorn R. van Doodewaerd,
  • Carl G. Figdor,
  • Gerbrand J. van der Heden van Noort,
  • Paul W. H. I. Parren,
  • Sandra Heskamp,
  • Huib Ovaa,
  • Martijn Verdoes,
  • Ferenc A. Scheeren

摘要

Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.